Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
When it comes to treating Duchenne muscular dystrophy, the steroid dosing debate just got more nuanced. A new real-world study found that daily corticosteroids preserve motor function significantly longer than intermittent regimens — but at a steep cost to bone health and growth. The findings underscore that there's no one-size-fits-all answer, and the longer patients are followed, the starker the trade-offs become.
When it comes to treating Duchenne muscular dystrophy (DMD), the choice between daily and intermittent corticosteroid (CS) regimens has always involved trade-offs — and new long-term real-world data published in the Journal of Neurology, Neurosurgery & Psychiatry shows those trade-offs only deepen over time. The retrospective study followed 219 DMD patients across three neuromuscular centers in Belgium and the Netherlands for nearly a decade, comparing daily deflazacort against an intermittent 10-days-on/10-days-off regimen.
Daily CS therapy came out ahead on motor outcomes: patients walked nearly four years longer (median age 15.0 vs. 11.0 years) and were far more likely to retain upper-limb function into adulthood. But the intermittent group fared much better on growth and bone health — standing nearly 30 cm taller at age 18 and experiencing far fewer fractures.
By the Numbers
Why it matters: These findings reinforce that DMD steroid management can't be one-size-fits-all. Clinicians and families must weigh motor preservation against serious skeletal risks — and emerging therapies like vamorolone, which may offer motor benefits with a better safety profile, could soon reshape this calculus entirely.
